Tourmaline Bio Inc. (TRML) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tourmaline Bio Inc. (TRML) has a cash flow conversion efficiency ratio of -0.078x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.26 Million) by net assets ($259.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Tourmaline Bio Inc. - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Tourmaline Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read TRML liabilities breakdown for a breakdown of total debt and financial obligations.
Tourmaline Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tourmaline Bio Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GMP Property SOCIMI SA
MC:YGMP
|
0.013x |
|
Henan Yicheng New Energy Co Ltd
SHE:300080
|
-0.017x |
|
Biotage AB
ST:BIOT
|
0.011x |
|
Treehouse Foods Inc
NYSE:THS
|
0.030x |
|
Grupo Herdez S.A.B. de C.V
MX:HERDEZ
|
0.020x |
|
Actions Technology Co Ltd
SHG:688049
|
0.045x |
|
Loma Negra Compañía Industrial Argentina Sociedad Anónima
F:8LN
|
0.032x |
|
SAMPYO Cement Co. Ltd
KQ:038500
|
0.061x |
Annual Cash Flow Conversion Efficiency for Tourmaline Bio Inc. (2019–2024)
The table below shows the annual cash flow conversion efficiency of Tourmaline Bio Inc. from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Tourmaline Bio Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $300.05 Million | $-77.26 Million | -0.257x | -88.02% |
| 2023-12-31 | $205.04 Million | $-28.08 Million | -0.137x | -141.84% |
| 2022-12-31 | $-19.73 Million | $-6.46 Million | 0.327x | +298.73% |
| 2021-12-31 | $242.81 Million | $-39.99 Million | -0.165x | -26.87% |
| 2020-12-31 | $148.00 Million | $-19.21 Million | -0.130x | +70.90% |
| 2019-12-31 | $39.59 Million | $-17.66 Million | -0.446x | -- |
About Tourmaline Bio Inc.
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline c… Read more